ICU Medical Announces Time of Fourth Quarter 2025 Earnings Conference Call
Get Alerts ICUI Hot Sheet
Join SI Premium – FREE
SAN CLEMENTE, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its fourth quarter 2025 earnings release and conference call.
The Company will release its fourth quarter 2025 results on Thursday, February 19, 2026 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Thursday, February 19, 2026. The call can be accessed at (800) 274-8461, conference ID “ICUMED”. The conference call will be simultaneously available by webcast, which can be accessed by going to the Company's website at www.icumed.com, clicking on the Investors tab, clicking on the Webcast icon and following the prompts. The webcast will also be available by replay.
About ICU Medical
ICU Medical (Nasdaq: ICUI) is a global leader in infusion systems, infusion consumables and high-value critical care products used in hospital, alternate site and home care settings. Our team is focused on providing quality, innovation and value to our clinical customers worldwide. ICU Medical is headquartered in San Clemente, California. More information about ICU Medical can be found at www.icumed.com.
CONTACT:
ICU Medical
Brian Bonnell, Chief Financial Officer
(949) 366-2183
ICR, Inc.
John Mills, Managing Partner
(646) 277-1254
Source: ICU Medical, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Is the global equity rally broadening? UBS weighs in
- FIA Hails Success of Landmark INDYCAR Freedom 250 Grand Prix as Motorsport Takes Centre Stage in Washington D.C.
- She Made it – the Youngest South African Woman to Swim the Channel
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share